See more : Moro Corporation (MRCR) Income Statement Analysis – Financial Results
Complete financial analysis of Nirvana Life Sciences Inc. (NIRV.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nirvana Life Sciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) Income Statement Analysis – Financial Results
- Danish Aerospace Company A/S (DAC.CO) Income Statement Analysis – Financial Results
- Somi Conveyor Beltings Limited (SOMICONVEY.NS) Income Statement Analysis – Financial Results
- Sintex Industries Limited (SINTEX.NS) Income Statement Analysis – Financial Results
- Pacific Gas and Electric Company PFD 1ST 5% (PCG-PC) Income Statement Analysis – Financial Results
Nirvana Life Sciences Inc. (NIRV.CN)
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. engages in the scientific research and development of therapeutic products derived from psychedelics. It also focuses on developing methodologies for extraction and purification of psychoactive compounds; and the improvement of propagation techniques for growing such biomass on a large scale. The company was incorporated in 2020 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 91.53 | 320.81K | 394.18 | 0.00 | 0.00 |
| General & Administrative | 498.49 | 407.57K | 314.24K | 74.83K | 159.69K |
| Selling & Marketing | 248.47 | 39.09K | 0.00 | 0.00 | 0.00 |
| SG&A | 992.29 | 446.66K | 314.24K | 74.83K | 159.69K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.48K | 1.18M | 314.24K | 74.83K | 159.69K |
| Cost & Expenses | 1.48K | 1.18M | 314.24K | 74.83K | 159.69K |
| Interest Income | 8.34 | 12.34K | 0.00 | 297.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.25K | 3.32K |
| Depreciation & Amortization | 91.64K | 91.65K | 28.72 | 171.86K | 161.14K |
| EBITDA | -1.08K | 3.40M | -314.24K | -74.53K | -159.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18K | -859.12K | -314.24K | -74.53K | -159.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -316.01 | -4.49M | -33.44 | 91.09K | 33.76K |
| Income Before Tax | -1.49K | -5.66M | -314.24K | 13.31K | -129.25K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.16 | 4.48M | -62.16 | 0.00 | 0.00 |
| Net Income | -1.49K | -5.65M | -314.24K | 13.31K | -129.25K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.15 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -0.04 | -0.15 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 33.94K | 36.52M | 33.02M | 33.02M | 33.02M |
| Weighted Avg Shares Out (Dil) | 33.94K | 36.52M | 33.02M | 33.02M | 33.02M |
Source: https://incomestatements.info
Category: Stock Reports